Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2021 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company...
November 03, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
November 01, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
October 11, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Promotion of Geoff Race to President

Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc....
September 30, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
September 08, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
August 02, 2021 07:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
July 26, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
June 10, 2021 08:30 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
May 28, 2021 08:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...